Recon: Germany to buy €300M stake in CureVac; AstraZeneca to supply EU with 400M doses of coronavirus vaccine

• FDA clears new version of Abbott's low-cost glucose monitor (Reuters)
• FDA approves GSK unit's drug to treat infants and children with HIV (Reuters) (STAT) (FDA)
• Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients (Reuters)
• Moderna COVID-19 vaccine appears to clear safety hurdle in mouse study (Reuters)
• White House pressure for a vaccine raises risk the US will approve one that doesn’t work (Politico)
• What’s at stake for industry in the pharmaceutical Space Race for a Covid-19 vaccine (STAT)
• A would-be chain of cancer centers wants to treat patients with Right to Try drugs, raising ethical questions (STAT)

• Germany to buy stake in CureVac as world races for COVID-19 vaccine (Reuters) (DW) (Financial Times)
• AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine (Reuters) (Bloomberg)
• AstraZeneca picks Catalent for packaging, supplying potential COVID-19 vaccine (Reuters)
• Shionogi boss cautions against hopes of early coronavirus vaccine (Financial Times)
• Israel in talks to buy coronavirus vaccine from Moderna, YNET reports (Reuters)
• Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19 (Economic Times)
• SK Biopharmaceuticals emerges from pandemic delays with pitch for $822M IPO (Endpoints)
• Coronavirus hitting the Americas hardest says World Health Organization (Reuters)
• Sinovac reveals positive preliminary data for COVID-19 vaccine (PMLive) (Endpoints) (STAT)
• Slowing the Coronavirus Is Speeding the Spread of Other Diseases (NYTimes)
• Up to 17 infected, 11 dead in new Ebola outbreak in Congo (Reuters)

• The First Covid Vaccines May Not Prevent Covid Infection (Bloomberg)
• Beijing district in 'wartime emergency' after virus cluster at major food market (Reuters)
• Mutation Allows Coronavirus to Infect More Cells, Study Finds. Scientists Urge Caution. (NYTimes)
• Masks significantly reduce infection risk, likely preventing thousands of COVID-19 cases -study (Reuters)
• Missing data veils coronavirus damage to minority communities (Politico)
• Guaranteed Ingredient in Any Coronavirus Vaccine? Thousands of Volunteers (NYTimes)
• Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients (Press)
• COVID-19: UK and Europe life sciences regulatory developments (Pharmafile)
• Coronavirus (COVID-19) Update: Daily Roundup June 12, 2020 (FDA)

• bluebird set for 2021 filing for sickle cell gene therapy LentiGlobin (PMLive)
• Will Clinical Trials Make a House Call? (LifeSciVC)
• No Signature Required: FDA Provides Temporary Relief from Obligation to Obtain Physical Signatures for Prescription Drug Samples (FDA Law Blog)
• EU regulators agree to review LEO's dermatitis drug (PharmaTimes)
• India DoP comes out with draft guidelines for Rs. 6,940 crore PLI scheme to promote domestic production of bulk drugs (PharmaBiz)
• PhRMA’s top communicator, a fierce defender of the industry, leaves for ExxonMobil (STAT)
• UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field? (Endpoints)
• Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention (Endpoints)
• Momenta clears a PhII hurdle on nipo — but one big rival remains well in the lead in this packed field (Endpoints) (STAT)
• A pioneering immuno-oncology researcher heads back to Dana-Farber as Eli Lilly’s cancer R&D group undergoes a wrenching changeup (Endpoints)
• Shattuck Labs ends silence with a shout-out on $118M raise for fusion protein work (Endpoints)
• On a hiring spree, Moderna recruits another Amgen vet for the executive committee; Repare, Forma set terms for IPO (Endpoints)
• EHA: AbbVie, Roche cement Venclexta's place in AML with survival win (Fierce)
• EHA: Johnson & Johnson's Darzalex branches out beyond myeloma with AL amyloidosis win (Fierce) (Endpoints)
• ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2 (Fierce)
• ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar (Fierce)
• FDA Approves JUVÉDERM® VOLUMA™ XC for Enhancement of the Chin Region (AbbVie)
• Plan to approach USFDA for re-inspection of key plants in next few months: Lupin (Economic Times)
• High-Priced Drugs For Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts And ICER (Pink Sheet)

• White House Left States On Their Own To Buy Ventilators. Inside Their Mad Scramble. (KHN)
• Medtronic deploys remote-controlled ventilators to lessen coronavirus exposure  (Fierce)
• ADA: Abbott's real-world data show FreeStyle Libre lowered A1c in Type 2 diabetes, with or without insulin (Fierce)
• ADA: Medtronic's next-gen artificial pancreas algorithm boosts time in range for young adults with Type 1 diabetes (Fierce)

• EMA Annual Report 2019 (EMA)
• Submissions received: Scope of regulated software based medical devices (TGA)
• Cherokee Nation Fights Bid To Nix Opioid Bellwether (Law360)
• CVS-Only HIV Drugs Deny Meaningful Access, 9th Circ. Told (Law360)
• Novartis Can't Duck Suit Over Cancer Drug Side Effects (Law360)